Syncona

Syncona
Company type	Public
Traded as	LSE: SYNC; FTSE 250 component
Founded	2012; 13 years ago
Headquarters	Saint Peter Port, Guernsey
Key people	Melanie Gee (chair)
Website	www.synconaltd.com

Syncona (LSE: SYNC) is a large British closed-ended investment trust dedicated to life science investments. Co-founded as Syncona Partners in 2012 by current CEO Martin Murphy and the Wellcome Trust,^[1] before merging with the Battle Against Cancer Investment Trust ('BACIT') in December 2016 and listing publicly,^[2] the company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.^[3] Its Chair is Melanie Gee.^[4]

References

^ "Wellcome Trust charity cuts stake in Syncona". Quoted Data. 14 March 2019. Retrieved 3 October 2025.
^ "U.K. investors team up to create $1.2B cancer-focused fund". Fierce Biotech. 7 November 2016. Retrieved 3 October 2025.
^ "BACIT Changes Name To Syncona After Investment Shift". Morning Star. 19 December 2016. Retrieved 4 March 2017.
^ "Tigue exiting Syncona as investment banker Gee joins board". Citywire. 6 June 2019. Retrieved 5 August 2021.

External links

Official site

[1] "Wellcome Trust charity cuts stake in Syncona". Quoted Data. 14 March 2019. Retrieved 3 October 2025.

[2] "U.K. investors team up to create $1.2B cancer-focused fund". Fierce Biotech. 7 November 2016. Retrieved 3 October 2025.

[3] "BACIT Changes Name To Syncona After Investment Shift". Morning Star. 19 December 2016. Retrieved 4 March 2017.

[4] "Tigue exiting Syncona as investment banker Gee joins board". Citywire. 6 June 2019. Retrieved 5 August 2021.

[1]

[2]

[3]

[4]